Corporate venture capital (CVC) continues to play a critical role in the innovation economy. But establishing a successful, long-term CVC program is not without its challenges.
A new book, Corporate Venturing: A Survival Guide, is a practical guidebook to developing high-performing CVCs. Cambia’s investment arm, Echo Health Ventures, is included as one of eight profiles of successful CVC programs and one of only two corporate health care investors featured.
Other profiles in the book include corporate venture programs from industries as diverse as financial services, transportation and technology:
- Capital One Growth Ventures
- Jet Blue Technology Ventures
- CSAA Insurance Group
- Munich Ventures
- Citi Ventures
- Intel Capital
- Merck Global Health Innovation Fund
“Corporate Venturing: A Survival Guide provides an inside look at several different models for long-term success,” said Rob Coppedge, CEO of Echo Health Ventures. “It is an invaluable guide for management teams to build and scale high impact, lasting corporate venture programs.”
Today, Echo comprises a team of approximately 15 investment and market development professionals, with offices in Durham, Seattle and Portland. Under the leadership of Rob Coppedge, CEO, and 20+- year veteran in health care investing, the program has grown to incorporate 25 portfolio companies across the health care IT and health care services sectors. Echo is a stage-agnostic, strategic health care investor, with preference for leading deals alongside experienced and like-minded syndicate partners.
For more details, read “New Health Evolution Report: Driving Value in Health Care Corporate Venture Capital” on the Echo Health Ventures blog or find Corporate Venturing: A Survival Guide on Amazon.
